Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTERICIN B versus LYNOZYFIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTERICIN B versus LYNOZYFIC.
AMPHOTERICIN B vs LYNOZYFIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin transporter (SERT) in the presynaptic terminal, increasing synaptic serotonin levels.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
1000 mg intravenously every 12 hours infused over 2 hours
None Documented
None Documented
Clinical Note
moderateAmphotericin B + Digoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin."
Clinical Note
moderateAmphotericin B + Digitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin."
Clinical Note
moderateAmphotericin B + Deslanoside
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside."
Clinical Note
moderateTerminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life is 12.4 hours (range 11.2–14.1 hours) in patients with normal renal function; allows twice-daily dosing for steady-state within 3 days.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion accounts for 25%; the remaining 10% is metabolized by hepatic CYP3A4-mediated oxidation.
Category C
Category C
Antifungal
Antifungal
Amphotericin B + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin."